Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in advanced BRCA1-like HER2-negative breast cancer
NCT02826512Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Progression Free Survival at 120 months. Started May 2018; status: terminated.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02826512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826512.